Remove

Pages Columns Lines where

Ţ5

	ľ
	F
	F
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	A
(NOTION SUBMISSION UNDER 57 OF R 1.33)	7

Application Number		09684861
Filing Date		2000-10-06
First Named Inventor Bilbin		, Paul
Art Unit		3623
Examiner Name	Pats,	Justin
Attorney Docket Number		PSTM0024/MRK

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	ate	Name of Pat of cited Docu	entee or Applicant iment	Rele	vant Passages or Relev es Appear	
	1									
If you wisl	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pat of cited Docu	entee or Applicant iment	Rele	s,Columns,Lines where vant Passages or Releves Ses Appear	
	1									
If you wish	h to ad	d additional U.S. Publ	ished Ap	plication	citatio	n information p	olease click the Ade	d butto	on. Add	
				FOREIG	3N PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1									
If you wisl	h to ad	d additional Foreign F	atent Do	cument	citation	information p	lease click the Add	buttor	n Add	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner	Cite	Include name of the a	uthor (in	CAPITA	AL LET	TERS), title of	the article (when a	pprop	riate), title of the item	

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

U.S.PATENTS

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			09684861		
Filing Date First Named Inventor Bilbin			2000-10-06		
		Biltbin	, Paul		
	Art Unit		3623		
	Examiner Name	Pats,	Justin		
Attorney Docket Number		er	PSTM0024/MRK		

Date Considered

1	EXAMINER MICHAEL M. THOMPSON, Notice of Allowance for USSN 09/680,654, dated 10/11/2011, pages 1-26, USPTO, Art Unit 3629, Altorney Docket No. PSTM0015MRK	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kins Codes of USPTO District Documents at smeril USPTO,000 or MRCP 901.6. ² Enter office that issued the document, by the No-vietta code (MIPO) assurant 51.3. ² For Apparent patient columnits, the natication of the year of the right of the Emptor must protocle to seem turner of the patient document. ⁴ Kind of coursent by the appropriate symbols as indicated on the document will be considered by the appropriate symbols as indicated on the document under WIPO Standard 51.7.6 if possible. ⁵ Applicant is to place a check mark here it is received to the coursent under WIPO Standard 51.7.6 if possible. ⁵ Applicant is to place a check mark here.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

- 47			09684861
			2000-10-06
		Biltbin	, Paul
Art Unit			3623
Examiner Name Pats,		Pats,	Justin
Attorney Docket Number		er	PSTM0024/MRK

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.9	7 and 1.98 t	o make the	appropriate	selection	s)	
---------------	-----------	--------------	------------	-------------	-----------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to g any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

Marilyn R. Khorsandi

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.							
Signature	/Marilyn R. Khorsandi/	Date (YYYY-MM-DD)	2011-10-21				

Registration Number

45 744

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the LISPTO to process) an application. Confidentiality is gowened by \$5.1.8.C. 12.2 and 3T CFR.

1.1.4 This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the LISPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatent and Trademant Officer, U.S. opparatment of Commonce, P.O. 8bs. 1450, Alexandric N.9. 2311-1450. DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs. 1450, Alexandrica, V.2. 2311.1469.

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested privacy is the principal purpose of which the information is used to patient. If you do not furnish the requested more private in the privacy of the privacy is a privacy of the privacy in the privacy of th

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.